(1 - 12 von 12
)
Paul Baas : ses chroniques sur le JDN
www.journaldunet.com
Paul Baas est Directeur général de Tools4ever France. Le groupe Tools4ever développe une gamme complète de solutions logicielles et propose des services ...
onkoserv - der aktuellste und unabhängige deutsche Informationsdienst...
www.onkoserv.de
Onkoserv ist der aktuellste deutsche Informationsdienst für die klinische Onkologie
Close-up: Paul Baas, Field Manager at Amsterdam ArenA ...essma.eu › news › article › close-u...
essma.eu
ESSMA interviewed Paul Baas, Field Manager at Amsterdam ArenA and responsible for the pitch since the season, about the daily ...
CheckMate 743 shows that dual immunotherapy, nivolumab + ...medicalxpress.com › news ›
medicalxpress.com
The study is presented by Paul Baas, M.D., from The Netherlands Cancer Institute and The University of Leiden, in Amsterdam. Nivolumab is an ...
Dr P. Baas - University of Amsterdam
www.uva.nl
Dr P. Baas (1958) has been appointed professor by special appointment of Thoracic Oncology at the Faculty of Medicine of the University of Amsterdam ( AMC-UvA). The chair was designated on behalf of the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL). Paul Baas focuses his ...
Ipilimumab, nivolumab shows promising control of mesothelioma
www.healio.com
The combination of nivolumab and ipilimumab showed a promising rate of 12-week disease control among patients with recurrent malignant pleural mesothelioma,...
First-line nivolumab-ipilimumab combination improves OS in ...www.healio.com › news › firstline-...
www.healio.com
Paul Baas, MD, researcher at Netherlands Cancer Institute and University of Leiden in Amsterdam, presented the results during the ...
IASLC WCLC 2020: CheckMate-743 shows that dual immunotherapy,...
ecancer.org
The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesot
Lung cancer researchers present new clinical trial data at...
www.globenewswire.com
CheckMate 743 Shows That Dual Immunotherapy, Nivolumab + Ipilimumab, Improves Overall Survival for Patients with Previously Untreated Mesothelioma
Les Solutions IAM de Tools4ever sélectionnées par l’UGAP - Kani RP
www.kanirp.com
Tools4ever éditeur de solutions logicielles leader du marché de la Gestion des Identités et des Accès vient d’être sélectionné par l’UGAP
Renowned Mesothelioma Researcher Discusses Promise of ...mesothelioma.net › renowned-mes...
mesothelioma.net
But according to renowned cancer researcher Paul Baas, MD, PhD of the Department of Thoracic Oncology at the Netherlands Cancer Institute, ...
checkmate 743 shows that dual immunotherapy EurekAlert!www.eurekalert.org › pub_releases
www.eurekalert.org
The study is presented by Paul Baas, M.D., from The Netherlands Cancer Institute and The University of Leiden, in Amsterdam. Watch a video ...
sortiert nach Relevanz / Datum